Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. 22504183

2012

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. 22504184

2012

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. 22504184

2012

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. 22504183

2012

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 22368270

2012

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 22368270

2012

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. 20733134

2010

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. 20733134

2010

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR Recurring mutations found by sequencing an acute myeloid leukemia genome. 19657110

2009

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR Recurring mutations found by sequencing an acute myeloid leukemia genome. 19657110

2009

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. 16857985

2006

dbSNP: rs121913487
rs121913487
T 0.800 CausalMutation CLINVAR A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. 16857985

2006

dbSNP: rs121913487
rs121913487
C 0.800 CausalMutation CLINVAR FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. 15374878

2005